

Structured expert elicitation to generate estimates for the administrative workload associated with prior authorization in pulmonary arterial hypertension (PAH)

AUTHORS: Akshay Muralidhar¹, Valentina Alvdzhan², Brett Carollo³, Tonya Zeiger⁴, Marinella Sandro⁵, Ankita Adhia⁶, Gabriela Gomez Rendon⁵, David Lopez², Korawin Triyasakorn⁶, Gregory Smith⁶, Danielle Riley⁶, Aimee Fox⁶, Olivia Dodd⁶, Jeremy Ord⁶, Kelly Marcello⁷

AFFILIATIONS: ¹Arizona Pulmonary Specialists, Scottsdale, Arizona, USA. ²University of California Los Angeles Health, University of California, Los Angeles School of Medicine, USA. ³Pulmonary Hypertension Center, Hartford, Connecticut, USA. ⁴Department of Pulmonary Medicine, Mayo Clinic Florida, USA. ⁵Johnson & Johnson, Titusville, New Jersey, USA. ⁶Adelphi Values PROVE, Bollington, Cheshire, UK. ⁷Norton Thoracic Institute St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Background

In the United States (US), access to specialty medications, including those used to treat pulmonary arterial hypertension (PAH), often require prior authorizations (PAs).¹ While intended to ensure appropriate use of treatments and manage associated costs, processes related to PAs may delay treatment initiation and reduce face-to-face time between healthcare professionals and patients. These effects can potentially divert time from direct patient care to administrative tasks, negatively impact clinical outcomes, and increase healthcare resource utilization (HCRU).²⁻⁵ Given the severity of PAH, these barriers may have particularly harmful consequences, underscoring the need to better understand the real-world impact of PAs in this population.⁵

Study objective



This research seeks to understand the administrative workload associated with PAs, with a focus on the impact on the management of patients with PAH.

Methods


A structured expert elicitation (SEE) methodology will be employed; this is a formal, quantitative process used to capture and combine expert judgments when empirical data are limited, uncertain, or absent. SEE techniques use structured interviews and statistical weighting to quantify expert uncertainty, aggregate estimates, and generate probability distributions for key parameters.^{6,7}

A double-blinded study consisting of three key stages will be conducted with 14 US-based healthcare professionals experienced in supporting patients with PAH:

- **Stage 1:** Qualitative interviews to explore key challenges of PA-related processes and contextual factors
- **Stage 2:** Structured quantitative SEE interviews to assess the burden of PA-related tasks
- **Stage 3:** A final consensus meeting to validate findings (Figure 1).

Stage 1 has been completed and the insights from the qualitative interviews are presented within this poster.

FIGURE 1: Overview of methodology.



Results

Overview of the experts



A total of **14 experts** completed the qualitative interviews, including **physicians** (n=6), **pharmacists** (n=5), **nurse practitioners** (n=2) and a **physician assistant** (n=1).



Most experts (n=8) reported having over **10 years of experience** managing administrative processes such as PAs; 4 experts had **2–5 years** of experience, and 2 experts reported **6–10 years** of experience.



Practice settings included **academic medical centers** (n=6), **accredited pulmonary hypertension (PH) centers** (n=4), **community hospitals** (n=3), and a **specialty pharmacy** (n=1).



Experts were located across the **Midwest** (n=5), **Northeast** (n=4), **West** (n=3), **Southeast** (n=1), and **Southwest** (n=1).




Among the experts, 5 experts reported spending **≥25% of their time on PA-related tasks per week**, 4 reported **15–24%**, and 3 reported **6–14%**.



Experts had experience across insurers, including **Medicare** (14/14), **private insurance** (14/14), and **Medicaid** (13/14). One expert also had experience with **Tricare**.

Summary of qualitative interview findings



References:

1. Bihari M. Prior Authorization: Overview, Purpose, Process. verywell health. 2. Forrester C. 2020. 3. Hallie Levine. Prior authorization: What is it, when might you need it, and how do you get it? 4. American Medical Association. 2024. 5. Association AL. 2024. 6. Bojke et al. 2021. 7. Bojke et al. 2017.



Factors contributing to delay

A variety of factors contribute to delays in the PA process for PAH therapies, including **insurer-driven requirements** (such as costs of therapy, step therapy [requiring patients to try lower-cost, often generic, therapies before gaining approval for higher-cost or newer alternatives]), and plan-specific processes), **documentation gaps, inefficient clinical workflows, breakdowns in communication, and continued reliance on faxes and phone calls.**

"[With regards to step therapy] ... That [step therapy] is probably one of our biggest issues... and then the patients just not wanting to sit there and have to fail the therapy to try and get something else. It is frustrating." - Physician

Administrative tools & support

While **electronic portals and manufacturer support teams have improved the efficiency of PAs for PAH therapies, inconsistent digital adoption, ongoing reliance on manual tracking, variable manufacturer assistance, and workflow differences** between internal and external specialty pharmacies may **limit the effectiveness** of administrative tools and **contribute to delays.**

"If it is a very streamlined one [a PA] that can be done electronically, then those are pretty quick. It is the ones that force us to use their own portals or their own papers or own fax, those take a long time" - Pharmacist



Impact of PA process

The PA process for PAH therapies **significantly increases the workload for clinical staff, diverting time away from patient care** for administrative tasks. For patients with PAH, the PA process can cause **substantial delays in therapy initiation, create financial burdens, and generate confusion, frustration, and anxiety**, especially when patients are unaware of the processes.

"[The PA] takes away from us being able to spend time on everything else with the patient, so whether it be following up on results that are coming in or patients calling with sick calls... we are given deadlines by insurance companies for doing these appeal letters... so all of that takes away from the actual patient care outside of getting their medications approved." - Nurse practitioner

Single-tablet combination therapy (STCT) and PA processes

Experts view **STCTs for PAH as beneficial for streamlining the treatment regimen**, but they also report that these therapies often face greater administrative hurdles in the PA process. These include **increased insurer scrutiny, more documentation**, and potentially **higher denial rates**, which may offset potential workflow efficiencies unless insurance approval is readily obtained.

"[PAs for STCT] I do not have to fill 2 forms... I do not have to submit 2 PAs... The third thing is convenience, right? My patient knows just this one pill to take every day... If insurance does not create any hurdles, that is our number one go-to. That is a gift of heaven." - Physician

Abbreviations:

EMR: Electronic medical record; HCRU: Healthcare resource utilization; PA: Prior authorization; PAH: Pulmonary arterial hypertension; PH: Pulmonary hypertension; SEE: Structured expert elicitation; STCT: Single-tablet combination therapy; US: United States.

Key takeaways and conclusions



Qualitative interviews with US-based experts with experience in supporting patients with PAH highlighted that managing PAs demands considerable involvement from clinical staff.



Experts believe that PAs may lead to delays in treatment initiation, create financial burdens, and subsequently lead to anxiety and frustration for patients.



Experts emphasized the operational complexity of managing PAH-related PAs, including variability in insurer requirements and coordination with specialty pharmacies.



Experts recommended that streamlining and standardizing PA processes, such as implementing unified electronic portals and more consistent insurer criteria, could help reduce administrative burden, accelerate treatment initiation, and improve patient outcomes in PAH.

Limitations

The limitations of this study are acknowledged:



The qualitative findings are based on a limited number of participants overall, from diverse roles and practice settings, which may limit the generalizability of findings across institution types and US regions/states.



Participants represented a range of professional backgrounds with varying degrees of involvement in PA processes, which may have influenced the emphasis and perspectives shared during interviews.

Next steps

Quantitative interviews using SEE methodology will be conducted to quantify the administrative workload associated with PAs.

Outputs from the SEE are anticipated in October 2025, the findings will quantify key PA-related challenges and define mitigation strategies based on physician input to reduce the PA-associated workload burden.

A consensus meeting will be held to discuss and validate the findings from the quantitative SEE interviews.

Acknowledgments

The authors sincerely thank all the participants who have contributed to the data collection through completion of the interviews completed to date.

Disclosures

MS, AA, GGR, DL, KT are employees of Johnson & Johnson, US. GS, DR, AF, OD, and JO are employees of Adelphi Values PROVE, who were contracted by Johnson & Johnson to conduct this research. AK, KM, VA, TZ, BC is a [placeholder].

Sponsored by Johnson & Johnson



Scan the QR code